Theravectys Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$24.8M
- Investors
-
7
Theravectys General Information
Description
Developer of a therapeutic vaccination technology designed for critical needs to prevent and treat infectious diseases and cancer. The company's vaccination technology assists in modulating the immune response through gene transfer into dendritic cells and supports patients and healthcare providers by developing prophylactic and therapeutic immunotherapies across a pipeline, enabling physicians to treat patients through a transfection mechanism to elicit a potent and targeted immune response.
Contact Information
Website
www.theravectys.comCorporate Office
- 25-28 Rue du Docteur Roux
- 75015 Paris
- France
Corporate Office
- 25-28 Rue du Docteur Roux
- 75015 Paris
- France
Theravectys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 15-Feb-2021 | $24.8M | Completed | Clinical Trials - Phase 1 | ||
| 9. Later Stage VC | 18-Apr-2017 | Completed | Clinical Trials - Phase 1 | |||
| 8. Grant | 26-Jan-2015 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 16-Oct-2013 | Completed | Clinical Trials - Phase 1 | |||
| 6. Debt - General | 29-May-2013 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 04-Sep-2012 | Completed | Clinical Trials - Phase 1 | |||
| 4. Debt - General | 01-Jan-2010 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 01-Jan-2008 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 01-Jan-2005 | $433K | Completed | Startup | ||
| 1. Early Stage VC | 01-Jan-2005 | Completed | Startup |
Theravectys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| O Shares |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Theravectys Comparisons
Industry
Financing
Details
Theravectys Competitors (59)
One of Theravectys’s 59 competitors is Cristal Therapeutics, a Venture Capital-Backed company based in Maastricht, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Virometix | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA |
Theravectys Patents
Theravectys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4729068-A1 | Lentiviral vector-based immunotherapy of prostate tumors | Pending | 16-Oct-2024 | ||
| WO-2026082898-A1 | Lentiviral vector-based immunotherapy of prostate tumors | Pending | 16-Oct-2024 | ||
| WO-2026077941-A1 | Lentiviral vectors targeting kras neoepitopes for cancer immunotherapy | Pending | 08-Oct-2024 | ||
| AU-2023362558-A1 | Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host | Pending | 21-Oct-2022 | ||
| EP-4604993-A2 | Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host | Pending | 21-Oct-2022 | A61P31/12 |
Theravectys Signals
Theravectys Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Bpifrance | Sovereign Wealth Fund | Minority | ||
| FGP Capital | Asset Manager | Minority | ||
| Financière IDAT | Corporation | Minority |
Theravectys FAQs
-
When was Theravectys founded?
Theravectys was founded in 2005.
-
Where is Theravectys headquartered?
Theravectys is headquartered in Paris, France.
-
What is the size of Theravectys?
Theravectys has 18 total employees.
-
What industry is Theravectys in?
Theravectys’s primary industry is Drug Discovery.
-
Is Theravectys a private or public company?
Theravectys is a Private company.
-
What is the current valuation of Theravectys?
The current valuation of Theravectys is .
-
What is Theravectys’s current revenue?
The current revenue for Theravectys is .
-
How much funding has Theravectys raised over time?
Theravectys has raised $64.7M.
-
Who are Theravectys’s investors?
, , Bpifrance, FGP Capital, and Financière IDAT are 5 of 7 investors who have invested in Theravectys.
-
Who are Theravectys’s competitors?
Cristal Therapeutics, Centrose, Virometix, Inovio Pharmaceuticals, and Iovance Biotherapeutics are some of the 59 competitors of Theravectys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process